pegcantratinib   Click here for help

GtoPdb Ligand ID: 11609

Synonyms: CT-327 | CT327 | K-252a-PEG2K | Pegylated K-252 | SNA-120 | SNA120
Compound class: Synthetic organic
Comment: Pegcantratinib (CT-327/SNA-120) is a clinical stage agent that inhibits the intracellular kinase domain of tropomyosin-related receptor kinase A (TrkA; NTRK1). TrkA is the high affinity receptor for nerve growth factor (NGF), and is a key target in pruritus, within the NGF-TrkA-TRPV1 pathway. As a TrkA inhibitor pegcantratinib is being evaluated as a potential topical treatment for inflammatory skin conditions. Chemically it is a 2kDa PEG derivative of K-252a that was originally developed by Sienna Biopharmaceuticals. PEG conjugation facilitates the delivery of high levels of the active ingredient to skin cells, and avoids the systemic side effects associated with an orally delivered version of the drug.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 113.26
Molecular weight 580.2
XLogP 5.11
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COCCOCCN1C(=O)OC2(C1=O)CC1OC2(C)n2c3ccccc3c3c2c2n1c1ccccc1c2c1c3CNC1=O
Isomeric SMILES COCCOCCN1C(=O)OC2(C1=O)CC1OC2(C)n2c3ccccc3c3c2c2n1c1ccccc1c2c1c3CNC1=O
InChI InChI=1S/C32H28N4O7/c1-31-32(29(38)34(30(39)43-32)11-12-41-14-13-40-2)15-22(42-31)35-20-9-5-3-7-17(20)24-25-19(16-33-28(25)37)23-18-8-4-6-10-21(18)36(31)27(23)26(24)35/h3-10,22H,11-16H2,1-2H3,(H,33,37)
InChI Key MTDVEOMKVDOULD-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Several phase 2 clinical trials of pegcantratinib have been completed in patients with atopic dermatitis or psoriasis [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03322137 Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris Phase 2 Interventional Sienna Labs
NCT01808157 A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis Phase 2 Interventional Creabilis SA
NCT01465282 Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris Phase 2 Interventional Creabilis SA 1